Promising combo falls short: lymphoma trial halted early
NCT ID NCT03547700
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tested two drugs, ixazomib and romidepsin, in people with a rare blood cancer called peripheral T-cell lymphoma that had returned or not responded to prior treatments. The trial was stopped early after enrolling only 11 participants, so the best dose could not be determined. The goal was to control the cancer, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL, PERIPHERAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Center (Wayne State University)
Detroit, Michigan, 48201, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.